{"success":true,"data":{"pressRelease":{"id":"155422","rtpr_id":"nACSqB0Z3a-20260929","ticker":"MDCE","exchange":"OTC","all_tickers":["MDCE"],"title":"Medical Care Technologies Inc. (OTCID:MDCE) Reports First-Pass Results From Volunteer Image Evaluation Inside Melanoma Scan Beta","author":"ACCESSWIRE","published_at":"2026-09-29T12:57:00.362Z","article_body":"MESA, AZ / ACCESS Newswire (https://www.accessnewswire.com/) / September 29,\n2026 / Medical Care Technologies Inc. (OTCID:MDCE) today reported first-pass\nresults from internal evaluation of its initial volunteer-submitted image\ndatasets for MDCE Melanoma Scan Beta.\n(https://pr.report/qvao)\nThe update follows the September 16 announcement that the first human\nvolunteer datasets had been received and the September 23 announcement that\ninternal review had begun. Those releases established collection and the start\nof analysis. This release reports what the first evaluation pass showed.\n\nUntil the volunteer phase, development relied on public dermatology archives,\nincluding HAM10000, ISIC Archive collections, and TCIA melanoma cohorts. The\nfirst volunteer set introduced uncontrolled capture conditions. First-pass\nreview was designed to answer a practical question: can those real-world\nphotographs move through the beta workflow?\n\nFirst-pass findings\n\nImage-quality scoring\nA substantial portion of the initial volunteer images met internal usability\nthresholds for focus, framing, and visible-area isolation. Images that did not\nmeet those thresholds were held out of mapping and comparison. That split is\nitself a result: the workflow can separate usable samples from captures that\nare too distant, poorly lit, or too compressed for a comparison pass.\n\nBody-map registration\nUsable images were successfully assigned to mapped body regions inside the\nbeta architecture. First-pass review indicated that volunteer photographs can\nbe placed on the interactive body map with enough locational consistency to\nsupport later retrieval of the same site.\n\nLongitudinal comparison\nWhere more than one usable image could be associated with the same mapped\narea, the platform completed side-by-side visual review. First-pass testing\nconfirmed that successive user-captured images can be organized for\nchange-over-time comparison. This finding concerns workflow function. It is\nnot a medical result.\n\nThese first-pass outcomes do not constitute clinical validation, performance\nbenchmarks, or diagnostic accuracy claims. They indicate that\nvolunteer-submitted photographs can enter the system, be quality-filtered, be\nmapped, and - when a second image exists - be compared.\n\nMDCE Melanoma Scan Beta is being developed as an AI-assisted imaging and\nbody-map monitoring application intended to help users catalog visible skin\nimages and review the same mapped area across sessions. The platform remains\nin beta-stage development. It has not received regulatory clearance and is not\nintended to diagnose, treat, cure, or prevent any disease or medical\ncondition. It is not a substitute for professional medical advice, screening,\nor evaluation by a qualified healthcare provider.\n\n\"The first pass did what we needed it to do,\" said Marshall Perkins, CEO of\nMedical Care Technologies. \"Real-world photos made it through quality scoring.\nThey registered to the body map. Where we had more than one image of the same\nsite, comparison ran. That is forward progress from collecting data to seeing\nthe workflow function on volunteer input.\"\n\nVolunteer participation is not a clinical diagnosis program. Any concern about\na skin change should be reviewed by a licensed clinician. Medical Care\nTechnologies will continue its multi-phase testing protocol and additional\nevaluation passes as more volunteer-submitted images are collected.\n\nInvestors and interested parties can learn more at:\nhttps://www.medicalcaretechnologies.com\n\nAbout Medical Care Technologies Inc.\nMedical Care Technologies Inc. (OTCID: MDCE) is a diversified technology\ncompany focused on the development and commercialization of artificial\nintelligence-powered applications spanning health, wellness, nutrition,\nlifestyle, and enterprise imaging analysis solutions. Visit:\nhttps://www.medicalcaretechnologies.com\n\nSafe Harbor Statement\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Forward-looking\nstatements are based on current expectations and assumptions, and actual\nresults may differ materially due to various risks and uncertainties. The\ncompany undertakes no obligation to update these statements except as required\nby law. Investors are cautioned not to place undue reliance on forward-looking\nstatements.\n\nContact Information:\nMedical Care Technologies Inc.\n1910 S. Stapley Drive, Suite 221, Mesa, AZ 85204\nPhone: +1 (480) 645-0750\nEmail: marshall@medicalcaretechnologies.com\nWebsite: https://www.medicalcaretechnologies.com\n\nSOURCE: Medical Care Technologies Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/medical-care-technologies-inc.-otcid-mdce-reports-first-pass-results-1228381)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSqB0Z3a-20260929","title":"Medical Care Technologies Inc. (OTCID:MDCE) Reports First-Pass Results From Volunteer Image Evaluation Inside Melanoma Scan Beta","author":"ACCESSWIRE","ticker":"MDCE","created":"2026-09-29T12:57:00.362Z","tickers":["MDCE"],"exchange":"OTC","article_body":"MESA, AZ / ACCESS Newswire (https://www.accessnewswire.com/) / September 29,\n2026 / Medical Care Technologies Inc. (OTCID:MDCE) today reported first-pass\nresults from internal evaluation of its initial volunteer-submitted image\ndatasets for MDCE Melanoma Scan Beta.\n(https://pr.report/qvao)\nThe update follows the September 16 announcement that the first human\nvolunteer datasets had been received and the September 23 announcement that\ninternal review had begun. Those releases established collection and the start\nof analysis. This release reports what the first evaluation pass showed.\n\nUntil the volunteer phase, development relied on public dermatology archives,\nincluding HAM10000, ISIC Archive collections, and TCIA melanoma cohorts. The\nfirst volunteer set introduced uncontrolled capture conditions. First-pass\nreview was designed to answer a practical question: can those real-world\nphotographs move through the beta workflow?\n\nFirst-pass findings\n\nImage-quality scoring\nA substantial portion of the initial volunteer images met internal usability\nthresholds for focus, framing, and visible-area isolation. Images that did not\nmeet those thresholds were held out of mapping and comparison. That split is\nitself a result: the workflow can separate usable samples from captures that\nare too distant, poorly lit, or too compressed for a comparison pass.\n\nBody-map registration\nUsable images were successfully assigned to mapped body regions inside the\nbeta architecture. First-pass review indicated that volunteer photographs can\nbe placed on the interactive body map with enough locational consistency to\nsupport later retrieval of the same site.\n\nLongitudinal comparison\nWhere more than one usable image could be associated with the same mapped\narea, the platform completed side-by-side visual review. First-pass testing\nconfirmed that successive user-captured images can be organized for\nchange-over-time comparison. This finding concerns workflow function. It is\nnot a medical result.\n\nThese first-pass outcomes do not constitute clinical validation, performance\nbenchmarks, or diagnostic accuracy claims. They indicate that\nvolunteer-submitted photographs can enter the system, be quality-filtered, be\nmapped, and - when a second image exists - be compared.\n\nMDCE Melanoma Scan Beta is being developed as an AI-assisted imaging and\nbody-map monitoring application intended to help users catalog visible skin\nimages and review the same mapped area across sessions. The platform remains\nin beta-stage development. It has not received regulatory clearance and is not\nintended to diagnose, treat, cure, or prevent any disease or medical\ncondition. It is not a substitute for professional medical advice, screening,\nor evaluation by a qualified healthcare provider.\n\n\"The first pass did what we needed it to do,\" said Marshall Perkins, CEO of\nMedical Care Technologies. \"Real-world photos made it through quality scoring.\nThey registered to the body map. Where we had more than one image of the same\nsite, comparison ran. That is forward progress from collecting data to seeing\nthe workflow function on volunteer input.\"\n\nVolunteer participation is not a clinical diagnosis program. Any concern about\na skin change should be reviewed by a licensed clinician. Medical Care\nTechnologies will continue its multi-phase testing protocol and additional\nevaluation passes as more volunteer-submitted images are collected.\n\nInvestors and interested parties can learn more at:\nhttps://www.medicalcaretechnologies.com\n\nAbout Medical Care Technologies Inc.\nMedical Care Technologies Inc. (OTCID: MDCE) is a diversified technology\ncompany focused on the development and commercialization of artificial\nintelligence-powered applications spanning health, wellness, nutrition,\nlifestyle, and enterprise imaging analysis solutions. Visit:\nhttps://www.medicalcaretechnologies.com\n\nSafe Harbor Statement\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Forward-looking\nstatements are based on current expectations and assumptions, and actual\nresults may differ materially due to various risks and uncertainties. The\ncompany undertakes no obligation to update these statements except as required\nby law. Investors are cautioned not to place undue reliance on forward-looking\nstatements.\n\nContact Information:\nMedical Care Technologies Inc.\n1910 S. Stapley Drive, Suite 221, Mesa, AZ 85204\nPhone: +1 (480) 645-0750\nEmail: marshall@medicalcaretechnologies.com\nWebsite: https://www.medicalcaretechnologies.com\n\nSOURCE: Medical Care Technologies Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/medical-care-technologies-inc.-otcid-mdce-reports-first-pass-results-1228381)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-09-29T12:57:00.417211436Z","server_sent_at_ms":1790686620417},"received_at":"2026-09-29T12:57:00.499Z","source_url":"https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/medical-care-technologies-inc.-otcid-mdce-reports-first-pass-results-1228381"},"analysis":{"id":"144148","press_release_id":"155422","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["no clinical validation or performance benchmarks; workflow testing only","product has no regulatory clearance","micro-cap OTC issuer with recurring incremental beta-stage announcements"],"eventType":"operations_update","narrative":"Medical Care Technologies reported first-pass results from internal evaluation of volunteer-submitted images inside its MDCE Melanoma Scan Beta.\n\nA substantial portion of the images met internal usability thresholds for focus and framing, registered successfully to mapped body regions, and supported side-by-side change-over-time comparison when multiple images of the same site existed.\n\nThe company stresses these are workflow findings, not clinical validation, performance benchmarks, or diagnostic accuracy claims; the product remains beta-stage with no regulatory clearance.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine beta workflow progress for micro-cap AI app -- suppress or file under low-priority monitoring."},"keyFigures":{},"quotedText":"The first pass did what we needed it to do","namedEntities":{"people":[{"name":"Marshall Perkins","role":"CEO"}],"products":["MDCE Melanoma Scan Beta"],"companies":[{"name":"Medical Care Technologies Inc.","ticker":"MDCE","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Internal first-pass workflow check on volunteer images inside a beta-stage app; the company explicitly states these are not clinical validation, benchmarks, or diagnostic claims. Micro-cap operational update with no financial figures."},"tickerRelevance":{"others":[],"primary":"MDCE"},"globalImportance":8,"audienceRelevance":8,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap OTC","eventGravity":"non-clinical beta workflow update","issuerAuthored":true,"retailFavoriteBoost":0}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Medical Care Technologies reported first-pass results from internal evaluation of volunteer-submitted images inside its MDCE Melanoma Scan Beta.\n\nA substantial portion of the images met internal usability thresholds for focus and framing, registered successfully to mapped body regions, and supported side-by-side change-over-time comparison when multiple images of the same site existed.\n\nThe company stresses these are workflow findings, not clinical validation, performance benchmarks, or diagnostic accuracy claims; the product remains beta-stage with no regulatory clearance.","key_figures":{},"named_entities":{"people":[{"name":"Marshall Perkins","role":"CEO"}],"products":["MDCE Melanoma Scan Beta"],"companies":[{"name":"Medical Care Technologies Inc.","ticker":"MDCE","relationship":"filer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T12:57:04.894Z","global_importance":8,"audience_relevance":8,"importance_components":{"tickerTier":"micro-cap OTC","eventGravity":"non-clinical beta workflow update","issuerAuthored":true,"retailFavoriteBoost":0}},"durationMs":4382,"modelName":"glm-5.3-flashx"}}